A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers & acquisition (M&A). Also read: • Why did mergers... Read more
Sinopharm, a dominant name in the distribution of pharmaceutical and healthcare products in China, continues to grab a large... Read more
Australia emerged as the third largest country in terms of the total revenue generated by companies during the calendar year... Read more
US remained an unstirred focus for Indian pharmaceutical company Lupin as it went on achieving 16 approvals from US FDA and launched 11... Read more
A distinguished name in treating, diagnosing and managing sleep-disordered breathing (SDB) and other respiratory disorders, ResMed continues... Read more
Striking profit on a high note, Dr. Reddy's crossed $1.5 billion worth of business in 2012, marking a growth of 22 percent. Dr. Reddy's... Read more
Cipla, which is known for providing affordable drugs to cancer and HIV patients in developing countries, clocked a growth of 17 percent... Read more
North China Pharmaceutical Company (NCPC) faced a decline of around 26 percent in 2012. The company is principally engaged in the production... Read more
Yunnan Baiyao Group is expanding its forte in the domain of traditional Chinese medicines and is concentrating on strengthening its R&D... Read more
Ranbaxy became the first Indian firm to develop a new drug called Synriam for malaria, which is a health menace that claims half a million... Read more
China National Accord Medicines Corporation utilized 2012 as a year to speed up the transformation and upgrade scientific development by... Read more
Marking a strong presence of 100 years in the pharmaceutical sector in the year 2012, Sigma Pharmaceuticals retained its No 3 rank slot... Read more
Survey Box